Novo Nordisk and Eli Lilly Dominance Under Threat as Drugmakers Bet Big on Obesity Treatment

AstraZeneca PLC and other pharmaceutical companies are intensifying efforts to challenge Novo Nordisk A/S and Eli Lilly and Co.’s dominance in the obesity drug market, according to multiple industry reports and corporate filings. The shift comes as regulators approve new treatments and investors pour capital into biotech firms developing weight-loss therapies, creating a competitive landscape that could reshape the $27 billion global market for obesity medications.

The race gained momentum in 2026 as AstraZeneca, which already markets the diabetes drug Ozempic, announced plans to advance its obesity-focused pipeline, including a Phase III trial for a dual-action GLP-1 and GIP receptor agonist. The company’s CEO, Pascal Soriot, highlighted the opportunity in a June 2026 earnings call, stating, “The obesity market represents a significant unmet need, and we are committed to delivering differentiated therapies that address both weight management and metabolic health.”

Novo Nordisk and Eli Lilly currently control approximately 70% of the U.S. obesity drug market through their blockbuster medications, Wegovy (semaglutide) and Ozempic (also semaglutide), which were originally developed for diabetes but gained popularity for weight loss. However, regulatory hurdles and patent expirations have prompted competitors to accelerate research. Zealand Pharma A/S, a Danish biotech firm, recently partnered with Roche Holding AG to co-develop a novel peptide therapy, while Gilead Sciences Inc. and Amgen Inc. have filed patents for potential oral obesity drugs.

Market Dynamics and Investment Trends

Investors are betting on the sector’s growth potential, with the iShares U.S. Pharmaceuticals ETF rising 12% year-to-date as of June 2026. Analysts at J.P. Morgan note that “the obesity drug market is expanding rapidly, driven by rising prevalence of metabolic disorders and increased insurance coverage for weight-loss treatments.” The firm estimates the market could reach $50 billion by 2030, attracting both established players and startups.

Structure Therapeutics Inc., a New Orleans-based biotech, has drawn attention for its novel approach to targeting gut hormones. The company’s lead candidate, STP-100, entered Phase II trials in April 2026, with preliminary data showing a 15% average weight loss in participants over 12 weeks. “Our therapy offers a safer alternative to existing options, with fewer gastrointestinal side effects,” said Ray Stevens, Structure’s chief scientific officer.

However, challenges persist. Regulatory agencies, including the U.S. Food and Drug Administration (FDA), have increased scrutiny of obesity drugs following safety concerns linked to earlier treatments. In 2025, the FDA issued a warning about cardiovascular risks associated with certain GLP-1 agonists, prompting companies to prioritize long-term safety data in clinical trials.

Strategic Alliances and Pipeline Developments

Collaborations between pharmaceutical giants and biotech firms are becoming common. In May 2026, AstraZeneca partnered with a South Korean firm, CJ Healthcare, to co-develop a once-weekly injectable therapy. The deal, valued at $250 million upfront, underscores the industry’s focus on global expansion. “We aim to diversify our portfolio and tap into emerging markets where obesity rates are rising sharply,” said AstraZeneca’s head of global research, Mene Pangalos.

Eli Lilly has also expanded its footprint, securing a $1.2 billion licensing deal with a U.K.-based startup, Vivid Bioscience, to access its microbiome-targeting platform. The partnership is expected to yield a new class of obesity treatments by 2028. Meanwhile, Pfizer Inc. and Amgen are exploring mergers and acquisitions in the space, with reports suggesting both companies are in talks to acquire smaller firms with promising pipelines.

The competitive landscape has also sparked debates about pricing. Wegovy and Ozempic, which cost $1,000–$1,500 per month, have faced criticism for being inaccessible to lower-income patients. In response, some companies are exploring subscription models and partnerships with insurers. “We’re working with payers to ensure affordability without compromising innovation,” said a spokesperson for Novo Nordisk.

What’s Next for the Industry?

The coming years will test whether new entrants can disrupt the market. Key milestones include the FDA’s expected decision on AstraZeneca’s dual-action drug in late 2026 and the completion of Phase III trials for several competitors. Analysts at Goldman Sachs predict that “the entry of multiple players could drive down prices and increase patient access, but it may also lead to regulatory bottlenecks and patent disputes.”

For now, the race remains